Staphylococcus Aureus Clinical Trials

7 recruiting

Staphylococcus Aureus Trials at a Glance

24 actively recruiting trials for staphylococcus aureus are listed on ClinicalTrialsFinder across 6 cities in 16 countries. The largest study group is Phase 4 with 9 trials, with the heaviest enrollment activity in Montreal, Hamilton, and Calgary. Lead sponsors running staphylococcus aureus studies include Todd C. Lee MD MPH FIDSA, Region Skane, and University Hospital, Basel, Switzerland.

Browse staphylococcus aureus trials by phase

Treatments under study

About Staphylococcus Aureus Clinical Trials

Looking for clinical trials for Staphylococcus Aureus? There are currently 7 studies actively recruiting participants. Clinical trials offer access to new treatments before they are widely available, and every approved therapy in use today was first tested through a clinical trial.

Below you can browse trials, sign up for alerts when new Staphylococcus Aureus trials open, and view eligibility criteria for each study. Each listing includes the study phase, locations, and enrollment details.

Frequently Asked Questions

Common questions about Staphylococcus Aureus clinical trials

A clinical trial is a carefully designed research study that tests new medical treatments, drugs, devices, or approaches in human volunteers. Every approved medication and treatment available today was proven safe and effective through clinical trials.

All clinical trials are reviewed and approved by Institutional Review Boards (IRBs) — independent committees that evaluate patient safety. Trials follow strict protocols, and your health is monitored closely throughout. You can withdraw at any time.

Not necessarily. Many trials compare the new treatment against the current standard of care, meaning all participants receive active treatment. When placebos are used, they are typically combined with standard treatment, not given alone. The trial description will always specify the design.

Under the Affordable Care Act, most private insurers are required to cover routine patient care costs during a clinical trial. The sponsor typically covers the investigational treatment itself. Medicare also covers routine costs for qualifying trials.

Yes. Participation is completely voluntary. You can withdraw at any time, for any reason, without it affecting your access to standard medical care.

Each trial has specific eligibility criteria — including age, diagnosis, disease stage, prior treatments, and general health. Browse the trials listed above and check their eligibility sections. You can also contact the trial site directly to discuss your situation.

Showing 120 of 24 trials

Recruiting
Phase 1Phase 2

A Study to Evaluate AZD7760 Safety and Pharmacokinetics in Healthy Adults (Phase I) and Adults With End-stage Kidney Disease on Hemodialysis With a Central Venous Catheter (Phase IIa)

Staphylococcus Aureus
AstraZeneca231 enrolled42 locationsNCT06749457
Recruiting
Phase 4

Comparison of Cloxacillin and Benzylpenicillin in Penicillin Susceptible S. Aureus Bacteraemia

Staphylococcus Aureus Bloodstream Infections (BSI; Bacteremia)Staphylococcus Aureus BacteraemiaStaphylococcal Bacteraemia+1 more
Region Skane420 enrolled1 locationNCT06726395
Recruiting
Not Applicable

Linezolid Plus Standard of Care

Staphylococcus Aureus Bloodstream Infections (BSI; Bacteremia)
University Hospital, Basel, Switzerland606 enrolled12 locationsNCT06958835
Recruiting
Phase 4

Clopidogrel vs. Aspirin for Cardiovascular Risk Reduction in Patients With S. Aureus Bacteremia

Staphylococcus Aureus EndocarditisStaphylococcus Aureus SepticemiaStaphylococcus Aureus Bloodstream Infection
Todd C. Lee MD MPH FIDSA300 enrolled1 locationNCT06650488
Recruiting
Phase 4

Dabigatran vs. Oral Anti-Xa Inhibitors in S. Aureus Bacteremia

Staphylococcus Aureus BacteremiaStaphylococcus Aureus EndocarditisStaphylococcus Aureus Septicemia+3 more
McGill University Health Centre/Research Institute of the McGill University Health Centre300 enrolled1 locationNCT06650501
Recruiting
Phase 4

Daptomycin vs. Vancomycin for the Treatment of Methicillin Resistant S. Aureus Bacteremia

Staphylococcus Aureus BacteremiaStaphylococcus Aureus EndocarditisStaphylococcus Aureus Septicemia+2 more
Todd C. Lee MD MPH FIDSA300 enrolled14 locationsNCT06637332
Recruiting
Phase 2

Combination Cefazolin With Ertapenem for Methicillin-susceptible Staphylococcus Aureus Bacteremia

Staphylococcus Aureus BacteremiaStaphylococcus Aureus EndocarditisStaphylococcus Aureus Septicemia+1 more
Todd C. Lee MD MPH FIDSA60 enrolled5 locationsNCT04886284
Recruiting

Effectiveness of Screening and Decolonization of S. Aureus to Prevent S. Aureus Surgical Site Infections in Surgery Outpatients

Surgical Site InfectionsStaphylococcus Aureus Colonization
University of Minnesota250 enrolled1 locationNCT06378359
Recruiting
Phase 3

Adjunctive Rifampin for the Treatment of Prosthetic Valve Endocarditis Due to S. Aureus

Prosthetic Valve EndocarditisStaphylococcus Aureus Endocarditis
Todd C. Lee MD MPH FIDSA330 enrolled1 locationNCT07253688
Recruiting
Not Applicable

Echocardiography Versus no Echocardiography in S. Aureus Bacteraemia and VIRSTA Score < 3

Staphylococcus AureusBacteremiaInfective Endocarditis
Assistance Publique - Hôpitaux de Paris700 enrolled1 locationNCT06457386
Recruiting
Phase 4

Staphylococcus Aureus Network Adaptive Platform Trial

Staphylococcus Aureus Bacteremia
University of Melbourne8,000 enrolled151 locationsNCT05137119
Recruiting
Phase 1

Comparing Single Versus Repeat NMT on the Diversity of the Neonatal Nasal Microbiome

Staphylococcus AureusMicrobial ColonizationNeonatal Infection
Johns Hopkins University175 enrolled1 locationNCT06283355
Recruiting
Phase 4

Trimethoprim-sulfamethoxazole vs. Clindamycin for the Treatment of Children With Invasive MRSA Infections

Osteomyelitis AcuteMethicillin Resistant Staphylococcus Aureus
Indiana University100 enrolled1 locationNCT06982105
Recruiting
Phase 4

Decolonization Efficacy of Polyhexanide vs. Mupirocin

Staphylococcus AureusColonization, Asymptomatic
Swiss Paraplegic Research, Nottwil24 enrolled1 locationNCT06633588
Recruiting
Not Applicable

Evaluating Simplified Layered Consent for Clinical Trials

Staphylococcus Aureus Bacteremia
Sunnybrook Health Sciences Centre346 enrolled6 locationsNCT06168474
Recruiting
Phase 4

Interleukin-4Ra Blockade by Dupilumab Decreases Staphylococcus Colonization and Increases Microbial Diversity in CRSwNP

Staphylococcus AureusNasal Polyps
University of Virginia20 enrolled1 locationNCT05094570
Recruiting
Phase 2

Target Attainment of Continuous Infusion Flucloxacillin and Cefazolin Coupled With TDM vs. Standard of Care Treatment in Patients With Complicated S. Aureus Infection

Complicated Staphylococcus Aureus (S. Aureus) Infections (CSAI)
University Hospital, Basel, Switzerland36 enrolled1 locationNCT05655091
Recruiting
Phase 1

First-in-man Single-dose and Multiple Dose Study to Evaluate the Safety, Tolerability and Efficacy ofHY-133

Staphylococcus Aureus
University Hospital Tuebingen52 enrolled2 locationsNCT06290557
Recruiting

Identification and Validation of Clinical Phenotypes in Staphylococcus Aureus Bacteremia and Their Association With Mortality and Development of Complicated Bacteremia

Staphylococcus Aureus Bacteremia
Fundación Pública Andaluza para la gestión de la Investigación en Sevilla1,000 enrolled1 locationNCT06574399
Recruiting

Rifampicin Resistance in S. Aureus During and After Treatment for Latent Tuberculosis

Staphylococcus AureusLatent Tuberculosis
Region Skane100 enrolled1 locationNCT05073926